Multiple Sclerosis

Throughout the 96-week EVOLVE-MS-1 trial, the majority of patients with MS experienced stable outcomes with diroximel fumarate treatment.

In a case report, an HIV-positive patient with active multiple sclerosis showed reduced disease activity with tenofovir-containing antiretrovirals, suggesting potential MS treatment benefits.

Marisa McGinley, DO, a staff neurologist at Cleveland Clinic’s Mellen Center for MS Treatment and Research, provided forward thoughts on the healthcare reach of neurologists and care access for patients with multiple sclerosis.

An online shared decision-making tool showed feasibility in most patients with multiple sclerosis, with reported improvements in understanding treatment options and adherence to treatment.

The professor in the department of neurology with McGovern Medical School at UTHealth Houston discussed outcomes of a recent study exploring the specificity of T cells in the spinal fluid of patients diagnosed with multiple sclerosis.

A recent study demonstrated that concomitant sleep apnea syndrome may expedite cognitive decline, particularly in attention and concentration, among patients with multiple sclerosis.

The staff neurologist from the Mellen Center for MS Treatment and Research at the Cleveland Clinic provided perspective on recently published research showing geographic disparities to neurologists and multiple sclerosis centers. [WATCH TIME: 3 minutes]

Among the disease-modifying drugs (DMDs) for multiple sclerosis (MS), glatiramer acetate was associated with a lower hazard of hypertension, presenting a potential positive impact on cardiovascular health.

Here's the latest multidisciplinary MS research published online first in the International Journal of MS Care.

Using a sample of 350 pregnancies, the maintenance of natalizumab during pregnancy past the 30th week had both positive and negative impacts, suggesting a risk-benefit discussion may be needed before patients begin treatment.

Over 144 weeks of treatment, patients on CNM-Au8 demonstrated sustained improvements in low contrast vision, working memory, and information processing speed.

The professor in the department of neurology with McGovern Medical School at UTHealth Houston talked about findings from a recent study that investigated T cell specificity in the spinal fluid of patients with multiple sclerosis. [WATCH TIME: 10 minutes]

The associate professor of clinical neurology at University of California, Irvine School of Medicine talked about addressing the critical unmet needs in disability progression among patients with multiple sclerosis. [WATCH TIME: 3 minutes]

Months after the FDA cleared a phase 2 study in myasthenia gravis, KYV-101 is set to be assessed in a diverse cohort of refractory progressive multiple sclerosis.

Over the 12-week study, treatment with famciclovir failed to reduce the frequency of viral shedding, further adding to the complexity of the role of Epstein-Barr virus in MS.

Clinicians have begun to incorporate more holistic ways to approach the treatment of multiple sclerosis symptoms by focusing on better overall health, exercising, and dieting.

The cohort study was conducted using data from the Danish Multiple Sclerosis Registry for women with clinically isolated syndrome and relapsing remitting multiple sclerosis.

Identifying the best treatment strategy for Black or African American patients who are at risk for a more challenging clinical course is of great importance and represents a key unmet need in our field.

As the field of MS care turns its sights on addressing progressive disease, the need for more biomarkers of disease activity and therapeutic target engagement is perhaps greater than ever.

The Bruton tyrosine kinase inhibitor has been evaluated in 2 phase 3 trials, GEMINI 1 and GEMINI 2 (NCT04410978; NCT04410991), in patients with relapsing-remitting and relapsing secondary progressive MS.

In a NeurologyLive® Peer Exchange series, experts on the care of patients with multiple sclerosis offer recommendations for selecting and sequencing therapies used to treat patients with relapsing disease.

The field of MS is shifting focus to issues such as understanding and tracking disease progression, approaches to treatment initiation, and the roles of diet and exercise in pathogenesis and disease course.

In cognitively impaired vs unimpaired patients, investigators found functional connectivity decreases in DMNa and DMNp and increases in the right and left frontoparietal networks.

The director of the Mellen Center for MS Treatment and Research at Cleveland Clinic discussed when clinicians should anticipate new therapies to treat progressive MS. [WATCH TIME: 2 minutes]

Ilya Kister, MD, professor of neurology, NYU Grossman School of Medicine, discussed his surprising results from ECTRIMS, which found no evidence of wearing off with ocrelizumab (Ocrevus; Genentech).